Correction to: Efficacy and safety of artemether-lumefantrine and dihydroartemisinin-piperaquine for the treatment of uncomplicated Plasmodium falciparum malaria and prevalence of molecular markers associated with artemisinin and partner drug resistance in Uganda

Chris Ebong; Asadu Sserwanga; Jane Frances Namuganga; James Kapisi; Arthur Mpimbaza; Samuel Gonahasa; Victor Asua; Sam Gudoi; Ruth Kigozi; James Tibenderana; John Bosco Bwanika; Agaba Bosco; Denis Rubahika; Daniel Kyabayinze; Jimmy Opigo; Damian Rutazana; Gloria Sebikaari; Kassahun Belay; Mame Niang; Eric S. Halsey; Leah F. Moriarty; Naomi W. Lucchi; Samaly S.Svigel Souza; Sam L. Nsobya; Moses R. Kamya; Adoke Yeka

doi:10.1186/s12936-022-04049-1

Correction to: Efficacy and safety of artemether-lumefantrine and dihydroartemisinin-piperaquine for the treatment of uncomplicated Plasmodium falciparum malaria and prevalence of molecular markers associated with artemisinin and partner drug resistance in Uganda

Chris Ebong
, Asadu Sserwanga
, Jane Frances Namuganga
, James Kapisi
, Arthur Mpimbaza
, Samuel Gonahasa
, Victor Asua
, Sam Gudoi
, Ruth Kigozi
, James Tibenderana
, John Bosco Bwanika
, Agaba Bosco
, Denis Rubahika
, Daniel Kyabayinze
, Jimmy Opigo
, Damian Rutazana
, Gloria Sebikaari
, Kassahun Belay
, Mame Niang
, Eric S. Halsey

Leah F. Moriarty, Naomi W. Lucchi, Samaly S.Svigel Souza, Sam L. Nsobya, Moses R. Kamya, Adoke Yeka

Infectious Diseases Research Collaboration
USAID's Malaria Action Program for Districts
Uganda Ministry of Health
U.S. President’s Malaria Initiative
Centers for Disease Control and Prevention
Makerere University

Research output: Other contribution

2 Citations (Scopus)

Abstract

Following publication of the original article [1], it was brought to the publisher’s attention that incorrect details had been provided in the trial registration information of the article. Where it should read: Trial registration: The trial was also registered with the Pan African Clinical Trial Registry (https:// pactr. samrc. ac. za/) with study Trial No. PACTR201811640750761. It said: Trial registration: The trial was also registered with the ISRCTN registry with study Trial No. PACTR201811640750761. The original article has been updated accordingly.

Original language	English
Edition	1
Volume	21
DOIs	https://doi.org/10.1186/s12936-022-04049-1
Publication status	Published - 1 Dec 2022
Externally published	Yes

Publication series

Name	Malaria Journal
Publisher	BioMed Central Ltd
ISSN (Print)	1475-2875

UN SDGs

This output contributes to the following UN Sustainable Development Goals (SDGs)

SDG 3 Good Health and Well-being

Access to Document

10.1186/s12936-022-04049-1Licence: CC BY

Fingerprint

Dive into the research topics of 'Correction to: Efficacy and safety of artemether-lumefantrine and dihydroartemisinin-piperaquine for the treatment of uncomplicated Plasmodium falciparum malaria and prevalence of molecular markers associated with artemisinin and partner drug resistance in Uganda'. Together they form a unique fingerprint.

Efficacy and safety of artemether-lumefantrine and dihydroartemisinin-piperaquine for the treatment of uncomplicated Plasmodium falciparum malaria and prevalence of molecular markers associated with artemisinin and partner drug resistance in Uganda
Ebong, C., Sserwanga, A., Namuganga, J. F., Kapisi, J., Mpimbaza, A., Gonahasa, S., Asua, V., Gudoi, S., Kigozi, R., Tibenderana, J., Bwanika, J. B., Bosco, A., Rubahika, D., Kyabayinze, D., Opigo, J., Rutazana, D., Sebikaari, G., Belay, K., Niang, M. & Halsey, E. S. & 6 others, Moriarty, L. F., Lucchi, N. W., Souza, S. S. S., Nsobya, S. L., Kamya, M. R. & Yeka, A., 1 Dec 2021, In: Malaria Journal. 20, 1, 484.
Research output: Contribution to journal › Article › peer-review

Open Access
38 Citations (Scopus)

Cite this

Ebong, C., Sserwanga, A., Namuganga, J. F., Kapisi, J., Mpimbaza, A., Gonahasa, S., Asua, V., Gudoi, S., Kigozi, R., Tibenderana, J., Bwanika, J. B., Bosco, A., Rubahika, D., Kyabayinze, D., Opigo, J., Rutazana, D., Sebikaari, G., Belay, K., Niang, M., ... Yeka, A. (2022, Dec 1). Correction to: Efficacy and safety of artemether-lumefantrine and dihydroartemisinin-piperaquine for the treatment of uncomplicated Plasmodium falciparum malaria and prevalence of molecular markers associated with artemisinin and partner drug resistance in Uganda. (1 ed.) https://doi.org/10.1186/s12936-022-04049-1

@misc{6eb424128ae8419eb83e3733fa365262,

title = "Correction to: Efficacy and safety of artemether-lumefantrine and dihydroartemisinin-piperaquine for the treatment of uncomplicated Plasmodium falciparum malaria and prevalence of molecular markers associated with artemisinin and partner drug resistance in Uganda",

abstract = "Following publication of the original article [1], it was brought to the publisher{\textquoteright}s attention that incorrect details had been provided in the trial registration information of the article. Where it should read: Trial registration: The trial was also registered with the Pan African Clinical Trial Registry (https:// pactr. samrc. ac. za/) with study Trial No. PACTR201811640750761. It said: Trial registration: The trial was also registered with the ISRCTN registry with study Trial No. PACTR201811640750761. The original article has been updated accordingly.",

author = "Chris Ebong and Asadu Sserwanga and Namuganga, \{Jane Frances\} and James Kapisi and Arthur Mpimbaza and Samuel Gonahasa and Victor Asua and Sam Gudoi and Ruth Kigozi and James Tibenderana and Bwanika, \{John Bosco\} and Agaba Bosco and Denis Rubahika and Daniel Kyabayinze and Jimmy Opigo and Damian Rutazana and Gloria Sebikaari and Kassahun Belay and Mame Niang and Halsey, \{Eric S.\} and Moriarty, \{Leah F.\} and Lucchi, \{Naomi W.\} and Souza, \{Samaly S.Svigel\} and Nsobya, \{Sam L.\} and Kamya, \{Moses R.\} and Adoke Yeka",

year = "2022",

month = dec,

day = "1",

doi = "10.1186/s12936-022-04049-1",

language = "English",

volume = "21",

series = "Malaria Journal",

publisher = "BioMed Central Ltd",

edition = "1",

type = "Other",

}

Ebong, C, Sserwanga, A, Namuganga, JF, Kapisi, J, Mpimbaza, A, Gonahasa, S, Asua, V, Gudoi, S, Kigozi, R, Tibenderana, J, Bwanika, JB, Bosco, A, Rubahika, D, Kyabayinze, D, Opigo, J, Rutazana, D, Sebikaari, G, Belay, K, Niang, M, Halsey, ES, Moriarty, LF, Lucchi, NW, Souza, SSS, Nsobya, SL, Kamya, MR & Yeka, A 2022, Correction to: Efficacy and safety of artemether-lumefantrine and dihydroartemisinin-piperaquine for the treatment of uncomplicated Plasmodium falciparum malaria and prevalence of molecular markers associated with artemisinin and partner drug resistance in Uganda. https://doi.org/10.1186/s12936-022-04049-1

Correction to: Efficacy and safety of artemether-lumefantrine and dihydroartemisinin-piperaquine for the treatment of uncomplicated Plasmodium falciparum malaria and prevalence of molecular markers associated with artemisinin and partner drug resistance in Uganda. / Ebong, Chris; Sserwanga, Asadu; Namuganga, Jane Frances et al.
1 ed. 2022. (Malaria Journal).

Research output: Other contribution

TY - GEN

T1 - Correction to: Efficacy and safety of artemether-lumefantrine and dihydroartemisinin-piperaquine for the treatment of uncomplicated Plasmodium falciparum malaria and prevalence of molecular markers associated with artemisinin and partner drug resistance in Uganda

AU - Ebong, Chris

AU - Sserwanga, Asadu

AU - Namuganga, Jane Frances

AU - Kapisi, James

AU - Mpimbaza, Arthur

AU - Gonahasa, Samuel

AU - Asua, Victor

AU - Gudoi, Sam

AU - Kigozi, Ruth

AU - Tibenderana, James

AU - Bwanika, John Bosco

AU - Bosco, Agaba

AU - Rubahika, Denis

AU - Kyabayinze, Daniel

AU - Opigo, Jimmy

AU - Rutazana, Damian

AU - Sebikaari, Gloria

AU - Belay, Kassahun

AU - Niang, Mame

AU - Halsey, Eric S.

AU - Moriarty, Leah F.

AU - Lucchi, Naomi W.

AU - Souza, Samaly S.Svigel

AU - Nsobya, Sam L.

AU - Kamya, Moses R.

AU - Yeka, Adoke

PY - 2022/12/1

Y1 - 2022/12/1

N2 - Following publication of the original article [1], it was brought to the publisher’s attention that incorrect details had been provided in the trial registration information of the article. Where it should read: Trial registration: The trial was also registered with the Pan African Clinical Trial Registry (https:// pactr. samrc. ac. za/) with study Trial No. PACTR201811640750761. It said: Trial registration: The trial was also registered with the ISRCTN registry with study Trial No. PACTR201811640750761. The original article has been updated accordingly.

AB - Following publication of the original article [1], it was brought to the publisher’s attention that incorrect details had been provided in the trial registration information of the article. Where it should read: Trial registration: The trial was also registered with the Pan African Clinical Trial Registry (https:// pactr. samrc. ac. za/) with study Trial No. PACTR201811640750761. It said: Trial registration: The trial was also registered with the ISRCTN registry with study Trial No. PACTR201811640750761. The original article has been updated accordingly.

U2 - 10.1186/s12936-022-04049-1

DO - 10.1186/s12936-022-04049-1

M3 - Other contribution

VL - 21

T3 - Malaria Journal

ER -

Ebong C, Sserwanga A, Namuganga JF, Kapisi J, Mpimbaza A, Gonahasa S et al. Correction to: Efficacy and safety of artemether-lumefantrine and dihydroartemisinin-piperaquine for the treatment of uncomplicated Plasmodium falciparum malaria and prevalence of molecular markers associated with artemisinin and partner drug resistance in Uganda. 2022. doi: 10.1186/s12936-022-04049-1